Danaher Lands Under The Microscope

Danaher beat expectations, but one weak result from its most closely watched business was enough to catalyze its worst one-day selloff in 25 years. The life-sciences and diagnostics company reported second-quarter revenue of $6.27 billion, up 5.5% from a year earlier, while adjusted earnings increased 8% to $1.94 per share, topping the $1.84 analysts expected. Core revenue grew 3%, and adjusted free cash flow reached $1.3 billion. Shares nevertheless closed down 10.9% Tuesday at $179.01 after falling as low as $166.13, as investors focused on surprisingly sluggish bioprocessing growth.

The disappointing sample came from Danaher’s Biotechnology segment, where core revenue grew only 2.5% and bioprocessing sales increased at a low-single-digit rate. Management blamed the shortfall largely on the timing of customer projects and shipments, while noting that bioprocessing orders still grew at a mid-teens pace. Other parts of the company performed considerably better. Life Sciences core revenue increased 5.5%, its strongest performance in several years, while Diagnostics grew 2%, or approximately 5% excluding respiratory testing. That made the weakness relatively concentrated, but it landed in the business investors were counting on to lead Danaher’s recovery.

The outlook gave the market another troubling reading. Danaher narrowed its full-year core-revenue growth forecast to 3%–4% from 3%–6% and expects only 2%–3% growth during the third quarter, below the approximately 3.6% analysts anticipated. The company still raised its full-year adjusted earnings guidance to $8.45–$8.60 per share from $8.35–$8.55, helped by its better-than-expected second quarter and the earlier completion of its Masimo acquisition. The higher forecast offered some bottom-line support, but it did little to answer questions about how quickly Danaher’s core businesses can regain momentum.

The reaction looks severe for a company whose management still expects to exit 2026 with mid-single-digit core growth. Danaher now has to prove that postponed customer projects can turn into shipments quickly enough to deliver that acceleration. The orders remain healthy, but investor patience just tested negative.

Disclaimer: This content is for informational and entertainment purposes only and does not constitute financial or investment advice. The information provided may be outdated or contain inaccuracies. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions. Investing involves risk, including the potential loss of principal. Unless explicitly stated otherwise, neither Equiscreen, LLC nor its beneficial owners hold any financial interest in the companies mentioned in our articles, and we do not receive compensation for including them. Equiscreen, LLC and its beneficial owners may buy or sell securities of any company referenced in our content at any time and without prior notice, and nothing published by Equiscreen, LLC should be interpreted as a recommendation to buy, sell, or hold any security. Any paid content or income-related materials will be clearly identified as “Sponsored” or “Advertorial,” and corresponding income disclosures can be found at the bottom of the page. For additional information, please contact [email protected].

Top Gainers

Top Losers

U.S. Commodities

2234 N Federal Hwy # 1022
Boca Raton, FL 33431

(561) 264-5726